⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
REGN
Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner
globenewswire.com
SNY
REGN
BIIB
INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
accessnewswire.com
REGN
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight
globenewswire.com
AMRX
ARX
GSK
AZN
SNY
NVS
MRK
REGN
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
AQST
RAPT
ALGT
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
accessnewswire.com
REGN
Happening Next Week! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy’s 2026 New York CISO Summit. Be a Part of It. Register Now.
globenewswire.com
MSFT
PFE
BAC
CVS
FMS
DGX
VRTX
CMCSA
LAB
AMZN
GOOGL
NVDA
IBM
ORCL
AMD
INTC
META
ADBE
CRM
CSCO
ACN
TMO
UNH
JNJ
PG
XOM
CVX
KO
PEP
DIS
NFLX
TSLA
REGN
GILD
AMGN
BMY
MRNA
BIIB
CRSP
ROKU
DDOG
SNOW
PANW
ZS
CRWD
SMCI
ASML
QCOM
AMAT
MU
LRCX
KLAC
NXPI
ON
ADI
TXN
MCHP
AVGO
MRVL
PLTR
UPST
COIN
SOFI
PLUG
FCEL
SPCE
GOOG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
prnewswire.com
REGN
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
globenewswire.com
REGN
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Shareholders to Inquire about Securities Investigation
accessnewswire.com
REGN
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
globenewswire.com
CTMX
REGN